Ensysce Biosciences (NASDAQ:ENSC) Posts Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Ensysce Biosciences (NASDAQ:ENSC) issued its earnings results on Tuesday. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.37, Zacks reports. The business had revenue of $3.42 million for the quarter, compared to analysts’ expectations of $0.25 million. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%.

Ensysce Biosciences Stock Down 10.3 %

ENSC opened at $0.64 on Friday. The business has a 50-day moving average of $0.37 and a 200-day moving average of $0.45. Ensysce Biosciences has a fifty-two week low of $0.14 and a fifty-two week high of $2.06.

About Ensysce Biosciences

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.